Heat-shock protein 60 as a tool for novel therapeutic strategies that target the induction of regulatory T cells in human arthritis

Expert Opinion on Biological Therapy

Volumn 6, Issue 6, 2006, Pages 579-589

  Kamphuis, Sylvia ^b,c   Albani, Salvatore ^d,e   Prakken, Berent J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Androclus Therapeutics   (Italy)

Author keywords

Antigen specific immunotherapy; Arthritis; Autoimmune disease; Heat shock protein 60; JIA; Regulatory T cell

Indexed keywords

CANCER GROWTH FACTOR; EPITOPE; GAMMA INTERFERON; HEAT SHOCK PROTEIN 60; INTERLEUKIN 10; INTERLEUKIN 11 RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 5; MYELIN BASIC PROTEIN; TRANSCRIPTION FACTOR FOXP3;

ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DISEASE CONTROL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOTHERAPY; JUVENILE RHEUMATOID ARTHRITIS; MOLECULAR MIMICRY; NONHUMAN; PATHOGENESIS; PROTEIN INDUCTION; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVIEW;

ANIMALS; ARTHRITIS; ARTHRITIS, JUVENILE RHEUMATOID; AUTOIMMUNE DISEASES; CD4-POSITIVE T-LYMPHOCYTES; CHAPERONIN 60; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; INTERLEUKIN-10; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 33744809528     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.6.579     Document Type: Review

References (114)

1. MATZING ER P: Tolerance, danger, and the extended family. Annu. Rev. Immunol. (1994) 12:991-1045.
2. CHRISTEN U, VON HERRATH MG: Initiation of autoimmunity. Curr. Opin. Immunol. (2004) 16:759-767.
3. ARIF S, TREE TI, ASTILL TP et al: Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J. Clin. Invest. (2004) 113:451-463.
4. VAN BILSEN JH, VANDONGEN H, LARD LR et al.: Functional regulatory immune responses against human cartilage glycoprotein-39 in health versus proinflammatory responses in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA (2004) 101:17180-17185.
5. FEHERVARI Z, SAKAGUCHI S: CD4+ Tregs and immune control. J. Clin. Invest. (2004) 114:1209-1217.
6. MALOY KJ, POWRIE F: Regulatory T cells in the control of immune pathology. Nat. Immunol. (2001) 2:816-822.
7. BLUESTONE JA, ABBAS AK: Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. (2003) 3:253-257. In this report, the authors make and elaborate on the principal distinction between natural and induced (adaptive) Tregs.
8. SAKAGUCHI S: Naturally arising Foxp3-expressing CD25(+)CD4(+) regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. (2005) 6:345-352. Clear review of natural Tregs and their markers.
9. RONCAROLO MG, BACCHETTA R, BORDIGNON C, NARULA S, LEVINGS MK: Type 1 T regulatory cells. Immunol. Rev. (2001) 182:68-79.
10. O'GARRA A, STEINMAN L, GIJBELS K: CD4+ T-cell subsets in autoimmunity. Curr. Opin. Immunol. (1997) 9:872-883.
11. CHEN Y, KUCHROO VX, INOBE J, HAFLER DA, WEINER HL: Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science (1994) 265:1237-1240.
12. MOTTET C, UHLIG HH, POWRIE F: Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J. Immunol. (2003) 170:3939-3943.
13. CHEN ML, PITTET MJ, GORELIK L et al.: Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc. Natl. Acad. Sci. USA (2005) 102:419-424.
14. LEE MK, MOORE DJ, JARRETT BP et al.: Promotion of allograft survival by CD4+CD25+ regulatory T cells: evidence for in vivo inhibition of effector cell proliferation. J. Immunol. (2004) 172:6539-6544.
15. JI J, MASTERSON J, SUN J, SOONG L: CD4+CD25 + regulatory T cells restrain pathogenic responses during Leishmania amazonensis infection. J. Immunol. (2005) 174:7147-7153.
16. TAYLOR MD, LEGOFF L, HARRIS A, MALONE E, ALLEN JE, MAIZELS RM: Removal of regulatory T cell activity reverses hyporesponsiveness and leads to filanal parasite clearance in vivo. J. Immunol. (2005) 174:4924-4933.
17. SAKAGUCHI S, SAKAGUCHI N, ASANO M, ITOH M, TODA M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes-various autoimmune diseases. J. Immunol. (1995) 155:1151-1164.
18. ASANO M, TODA M, SAKAGUCHI N, SAKAGUCHI S: Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J. Exp. Med. (1996) 184:387-396.
19. BAECHER-ALLAN C, HAFLER DA: Suppressor T cells in human diseases. J. Exp. Med. (2004) 200:273-276. The authors present an elaborate overview of the role of natural Tregs in human disease.
20. DE KLEER IM, WEDDERBURN LR, TAAMS LS et al.: CD4+CD25(bright) regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J. Immunol. (2004) 172:6435-6443.
21. TAAMS L, VUKMANOVIC-STEJIC M, SALMON M, AKBAR A: Immune regulation by CD4+CD25+ regulatory T cells: implications for transplantation tolerance. Transplant. Immunol. (2003) 11:277-285.
22. SOMERSET DA, ZHENG Y, KILBY MD, SANSOM DM, DRAYSON MT: Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. Immunology (2004) 112:38-43.
23. JONULEIT H, SCHMITT E, KAKIRMAN H, STASSEN M, KNOP J, ENK AH: Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J. Exp. Med. (2002) 196:255-260.
24. DIECKMANN D, BRUETT CH, PLOETTNER H, LUTZ MB, SCHULERC: Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J. Exp. Med. (2002) 196:247-253.
25. ANNUNZIATO F, COSMI L, LIOTTA F et al.: Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes. J. Exp. Med. (2002) 196:379-387.
26. LEVINGS MK, BACCHETTA R, SCHULZ U, RONCAROLO MG: The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells. Int. Arch. Allergy Immunol. (2002) 129:263-276.
27. high T cells as a homogenous human Treg population with high suppressive capacity.
28. BAECHER-ALLAN C, VIGLIETTA V, HAFLER DA: Human CD4+CD25+ regulatory T cells. Semin. Immunol. (2004) 16:89-98.
29. ZHENG SG, WANG JH, GRAY JD, SOUCIER H, HORWITZ DA: Natural and induced CD4+CD25+ cells educate CD4+. J. Immunol. (2004) 172:5213-5221.
30. WALKER MR, KASPROWICZ DJ, GERSUK VH et al: Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+. J. Clin. Invest. (2003) 112:1437-1443.
31. DUTHOIT CT, NGUYEN P, GEIGERTL: Antigen nonspecific suppression of T cell responses by activated stimulation-refractory CD4+ T cells. J. Immunol. (2004) 172:2238-2246.
32. CHEN W, JIN W, HARDEGEN N et al.: Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. (2003) 198:1875-1886.
33. FANTINI MC, BECKER C, MONTELEONE G, PALLONE F, GALLE PR, NEURATH MF: Cutting edge: TGF-beta induces a regulatory phenotype in CD4+. J. Immunol. (2004) 172:5149-5153.
34. MORGAN ME, VAN BILSEN JH, BAKKER AM et al.: Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. Hum. Immunol. (2005) 66:13-20.
35. VON HERRATH MG, HARRISON LC: Antigen-induced regulatory T cells in autoimmunity. Nat. Rev. Immunol. (2003) 3:223-232. Excellent overview of the role of induced Tregs in autoimmune disease.
36. FUKAURA H, KENT SC, PIETRUSEWICZ MJ, KHOURY SJ, WEINER HL, HAFLER DA: Induction of circulating myelin basic protein and proteolipid prorein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J. Clin. Invest. (1996) 98:70-77.
37. GROUX H, O'GARRA A, BIGLER M et al: A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature (1997) 389:737-742.
38. MILLS KH, MCGUIRK P: Antigen-specific regulatory T cells-their induction and role in infection. Semin. Immunol. (2004) 16:107-117.
39. MATTNER F, SMIROLDO S, GALBIATI F et al.: Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D(3). Eur. J. Immunol. (2000) 30:498-508.
40. LEVINGS MK, GREGORI S, TRESOLDI E, CAZZANIGA S, BONINI C, RONCAROLO MG: Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood (2005) 105:1162-1169.
41. RONCAROLO MG, GREGORI S, LEVINGS M: Type 1 T regulatory cells and their relationship with CD4+CD25+ T regulatory cells. Novartis Found. Symp. (2003) 252:115-127.
42. BARRAT FJ, CUA DJ, BOONSTRA A et al.: In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med. (2002) 195:603-616.
43. WRAITH DC: Role of interleukin-10 in the induction and function of natural and antigen-induced regulatory T cells. J. Autoimmun. (2003) 20:273-275.
44. RONCAROLO MG, BATTAGLIA M, GREGORI S: The role of interleukin 10 in the control of autoimmunity. J. Autoimmun. (2003) 20:269-272.
45. MOORE KW, DE WAAL MR, COFFMAN RL, O'GARRA A: Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. (2001) 19:683-765.
46. SUNDSTEDT A, O'NEILL EJ, NICOLSON KS, WRAITH DC: Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo. J. Immunol. (2003) 170:1240-1248.
47. BURKHART C, LIU GY, ANDERTON SM, METZLER B, WRAITH DC: Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis: a role for IL-10. Int. Immunol. (1999) 11(10):1625-1634.
48. TANG Q, HENRIKSEN KJ, BI M et al.: In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. (2004) 199:1455-1465.
49. TARBELL KV, YAMAZAKI S, OLSON K, TOY P, STEINMAN RM: CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J. Exp. Med. (2004) 199:1467-1477.
50. HORWITZ DA, ZHENG SG, GRAY JD, WANG JH, OHTSUKA K, YAMAGIWA S: Regulatory T cells generated ex vivo as an approach for the therapy of autoimmune disease. Semin. Immunol. (2004) 16:135-143.
51. BLUESTONE JA: Regulatory T-cell therapy: is it ready for the clinic? Nat. Rev. Immunol. (2005) 5:343-349.
52. POCKLEY AG: Heat shock proteins as regulators of the immune response. Lancet (2003) 362:469-476.
53. LINDQUIST S, CRAIG EA: The heat shock proteins. Annu. Rev. Genet. (1988) 22:631-677.
54. JINDAL S, DUDANI AK, SINGH B, HARLEY CB, GUPTA RS: Primary structure of a human mitochondrial protein homologous to the bacterial and plant chaperonins and to the 65-kilodalton mycobacterial antigen. Mol. Cell. Biol. (1989) 9:2279-2283.
55. KAUFFMANN SH: Heat shock proteins and the immune response. Immunol. Today (1990) 11:129-136.
56. KAUFMANN SH, VATH U, THOLE JE, VAN EMBDEN JD, EMMRICH F: Enumeration of T cells reactive with Mycobacterium tuberculosis organisms and specific for the recombinant mycobacterial 64-kDa protein. Eur. J. Immunol. (1987) 17:351-357.
57. SANCHEZ-CAMPILLO M, BINI L, COMANDUCCI M et al.: Identification of immunoreactive proteins of Chlamydia trachomatis by western blot analysis of a two-dimensional electrophoresis map with patient sera. Electrophoresis (1999) 20:2269-2279.
58. MATTHEWS RC, MARESCA B, BURNIE JP et al.: Stress proteins in fungal diseases. Med. Mycol. (1998) 36(Suppl. 1):45-51.
59. OLDSTONE MB: Molecular mimicry and immune-mediated diseases. FASEB J. (1998) 12:1255-1265.
60. VAN EDEN W, VAN DER ZEE R, PRAKKEN B: Heat-shock proteins induce T-cell regulation of chronic inflammation. Nat. Rev. Immunol. (2005) 5:318-330. This review links immune reactivity to HSPs with induction of tolerogenic immune responses, and is an elegant overview of the role of HSPs in immune regulation.
61. ANDERTON SM, VAN DER ZEE R, PRAKKEN B, NOORDZIJ A, VAN EDEN W: Activation of T-cells recognizing self 60 kDa heat shock protein can protect against experimental arthritis. J. Exp. Med. (1995) 181:943-952. In this study, the authors demonstrate for the first time that autoimmune responses to conserved sequences of self-HSPs can indeed protect against autoimmune disease, and is based on T cell crossreactivity between the microbial and rat HSP peptide.
62. QUINTANA FJ, CARMI P, MOR F, COHEN IR: Inhibition of adjuvant arthritis by a DNA vaccine encoding human heat shock protein 60. J. Immunol. (2002) 169(6):3422-3428.
63. PRAKKEN BJ, WENDLING U, VAN DER ZEE R, RUTTEN VP, KUIS W, VAN EDEN W: Induction of IL-10 and inhibition of experimental arthritis are specific features of microbial heat shock proteins that are absent for other evolutionarily conserved immunodominant proteins. J. Immunol. (2001) 167(8):4147-4153.
64. VAN DE BROEK MF, HOGERVORST EJ, VAN BRUGGEN MC, VAN EDEN W, VAN DER ZEE R, VAN DEN BERG W: Protection against streptococcal cell wall-induced arthritis by pretreatment with the 65-kD mycobacterial heat shock protein. J. Exp. Med. (1989) 170:449-466.
65. THOMPSON SJ, ROOK GA, BREALEY RJ, VAN DER ZEE R, ELSON CJ: Autoimmune reactions to heat-shock proteins in pristane-induced arthritis. Eur. J. Immunol. (1990) 20:2479-2484.
66. ELIAS D, ABLAMUNITS V, BIRK OS, CARMI P, KÖNEN-WAISMAN S, COHEN IR: Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmumty to various β-cell antigens. Diabetes (1997) 46:758-764.
67. BIRNBAUM G, KOTILINEK L, MILLER SD et al.: Heat shock proteins and experimental autoimmune encephalomyelitis. II: environmental infection and extra-neuraxial inflammation alter the course of chronic relapsing encephalomyelitis. J. NeuroImmunol. (1998) 90:149-161.
68. WENDLING U, PAUL L, VAN DER ZEE R, PRAKKEN B, SINGH M, VAN EDEN W: A conserved mycobacterial heat shock protein (hsp) 70 sequence prevents adjuvant arthritis upon nasal administration and induces IL-10-producing T cells that cross-react with the mammalian self-hsp70 homologue. J. Immunol (2000) 164:2711-2717.
69. DE GRAEFF-MEEDER ER, VAN DER ZEE R, RIJKERS GT et al: Recognition of human 60 kD heat shock protein by mononuclear cells from patients with juvenile chronic arthritis. Lancet (1991) 337:1368-1372.
70. SPAHN TW, HEIMANN H, DUCHMANN R, VAN DER ZEE R, MEYER ZUM BUSCHENFELDE KH, LOHSE AW: Cellular and humoral immunity to the 60-kD heat shock protein in inflammatory bowel disease. Digestion (1997) 58:469-475.
71. RAMAGE JM, GASTON JS: Depressed proliferative responses by peripheral blood mononuclear cells from early arthritis patients to mycobacterial heat shock protein 60. Rheumatology (Oxford) (1999) 38:631-635.
72. ABULAFIA-LAPID R, ELIAS D, RAZ I, KEREN-ZUR Y, ATLAN H, COHEN IR: T cell proliferative responses of type 1 Diabetes patients and healthy individuals to human hsp60 and its peptides. J. Autoimmun. (1999) 12:121-129.
73. BASON C, CORROCHER R, LUNARDI C et al.: Interaction of antibodies against cytomegalovirus with heat-shock protein 60 in pathogenesis of atherosclerosis. Lancet (2003) 362:1971-1977.
74. CORRIGALL VM, BODMAN-SMITH MD, FIFE MS et al: The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis. J. Immunol. (2001) 166:1492-1498.
75. WOO P: Cytokines and juvenile idiopathic arthritis. Curr. Rheumatol. Rep. (2002) 4:452-457.
76. PETTY RE, SOUTHWOOD TR, MANNERS P et al.: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. (2004) 31:390-392.
77. CRAWLEY E, KON S, WOO P: Hereditary predisposition to low interleukin-10 production in children with extended oligoarticular juvenile idiopathic arthritis. Rheumatology (Oxford) (2001) 40:574-578.
78. MURRAY KJ, GROM AA, THOMPSON SD, LIEUWEN D, PASSO MH, GLASS DN: Contrasting cytokine profiles in the synovium of different forms of juvenile rheumatoid arthritis and juvenile spondyloarthropathy: prominence of interleukin 4 in restricted disease. J. Rheumatol. (1998) 25:1388-1398.
79. THOMPSON SD, LUYRINK LK, GRAHAM TB et al.: Chemokine receptor CCR4 on CD4+ T cells in juvenile rheumatoid arthritis synovial fluid defines a subset of cells with increased IL-4:IFN-gamma mRNA ratios. J. Immunol. (2001) 166:6899-6906.
80. IELLEM A, MARIANI M, LANG R et al.: Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J. Exp. Med. (2001) 194:847-853.
81. RUPRECHT CR, GATTORNO M, FERLITO F et al.: Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J. Exp. Med. (2005) 201:1793-1803.
82. LIFE R HASSEL A, WILLIAMS K et al.: Responses to Gram-negative enteric bacterial antigens by synovial T cells from patients with juvenile chronic arthritis: recognition of heat shock protein hsp60. J. Rheumatol. (1993) 20:1388-1396.
83. ALBANI S, RAVELLI A, MASSA M et al.: Immune responses to the Escherichia coli dnaJ heat shock protein in juvenile rheumatoid arthritis and their correlation with disease activity. J. Pediatr. (1994) 124:561-565.
84. DE GRAEFF-MEEDER ER, VAN EDEN W, RIJKERS GT et al.: Juvenile chronic arthritis: T cell reactivity to human HSP60 in patients with a favourable course of arthritis. J. Clin. Invest. (1995) 95:934-940.
85. PRAKKEN AB, VAN EDEN W, RIJKERS GT et al.: Autoreactivity to human heat-shock protein 60 predicts disease remission in oligoarticular juvenile rheumatoid arthritis. Arthritis Rheum. (1996) 39:1826-1832.
86. DE KLEER IM, KAMPHUIS SM, RIJKERS GT et al.: The spontaneous remission of juvenile idiopathic arthritis is characterized by CD30+ T cells directed to human heat-shock protein 60 capable of producing the regulatory cytokine interleukin-10. Arthritis Rheum. (2003) 48:2001-2010.
87. SOUTHWOOD S, SIDNEY J, KONDO A et al.: Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. (1998) 160:3363-3373.
88. SETTE A: Tools of the trade in vaccine design. Science (2000) 290:2074-2075.
89. KAMPHUIS S, KUIS W, DE JAGER W et al.: Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis. Lancet (2005) 366:50-56. This study identifies immunomodulatory HSP peptides that are good candidates for antigen-specific immune therapy in JIA.
90. BITAR DM, WHITACRE CC: Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. Cell. Immunol. (1988) 112:364-370.
91. ANDERTON SM, WRAITH DC: Hierarchy in the ability of T cell epitopes to induce peripheral tolerance to antigens from myelin. Eur. J. Immunol. (1998) 28:1251-1261.
92. LIU JQ, BAI XF, SHI FD et al.: Inhibition of experimental autoimmune encephalomyelitis in Lewis rats by nasal administration of encephalitogenic MBP peptides: synergistic effects of MBP 68-86 and 87-99. Int. Immunol. (1998) 10:1139-1148.
93. STAINES NA, HARPER N, WARD FJ, MALMSTRÖM V, HOLMDAHL R, BANSAL S: Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Clin. Exp. Immunol. (1996) 103:368-375.
94. PRAKKEN BJ, VAN DER ZEE R, ANDERTON SM, VAN KOOTEN PJ, KUIS W VAN EDEN W: Peptide induced nasal tolerance for a mycobacterial hsp60 T cell epitope in rats suppresses both adjuvant arthritis and non-microbially induced experimental arthritis. Proc. Natl. Acad. Sci. USA (1997) 94:3284-3289.
95. TIAN Y, ATKINSON MA, CLARE-SALZLER M et al.: Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J. Exp. Med. (1996) 183:1561-1567.
96. DANIEL D, WEGMANN DR: Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc. Natl. Acad. Sci. USA (1996) 93:956-960.
97. AL-SABBAGH A, NELSON PA, AKSELBAND Y, SOBEL RA, WEINER HL: Antigen-driven peripheral immune tolerance:suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis by aerosol administration of myelin basic protein or type II collagen. Cell. Immunol. (1996) 171:111-119.
98. NAGLER-ANDERSON C, BOBER LA, ROBINSON ME, SISKIND GW, THORBECKE GJ: Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc. Natl. Acad. Sci. USA (1986) 83:7443-7446.
99. CHEN W, JIN W, COOK M, WEINER HL, WAHL SM: Oral delivery of group A streptococcal cell walls augments circulating TGF-beta and suppresses streptococcal cell wall arthritis. J. Immunol. (1998) 161:6297-6304.
100. MA SW, ZHAO DL, YIN ZQ et al.: Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance. Nat. Med. (1997) 3:793-796.
101. MA S, HUANG Y, YIN Z, MENASSA R, BRANDLE JE, JEVNIKAR AM: Induction of oral tolerance to prevent diabetes with transgenic plants requires glutamic acid decarboxylase (GAD) and IL-4. Proc. Natl. Acad. Sci. USA (2004) 101:5680-5685.
102. STEINMAN L: Immune therapy for autoimmune diseases. Science (2004) 305:212-216.
103. TANAKA S, KIMURA Y, MITANI A et al.: Activation of T cells recognizing an epitope of heat-shock protein 70 can protect against rat adjuvant arthritis. J. Immunol. (1999) 163:5560-5565.
104. DURAI M, GUPTA RS, MOUDGIL KD: The T cells specific for the carboxyl-terminal determinants of self (rat) heat-shock protein 65 escape tolerance induction and are involved in regulation of autoimmune arthritis. J. Immunol. (2004) 172:2795-2802.
105. WEINER HL: Current issues in the treatment of human diseases by mucosal tolerance. Ann. NY Acad. Sci. (2004) 1029:211-224.
106. TRENTHAM DE, DYNESIUS-TRENTHAM RA, ORAV JE el al.: Effects of oral administration of type II collagen on rheumatoid arthritis. Science (1993) 261:1727-1730.
107. WEINER HL, MACKIN GA, MATSUI M et al.: Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science (1993) 259:1321-1324.
108. MCKOWN KM, CARBONE LD, KAPLAN SB et al.: Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis. Arthritis Rheum. (1999) 42:1204-1208.
109. POZZILLI P, PITOCCO D, VISALLI N et al.: No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia (2000) 43:1000-1004.
110. RAZI, ELIAS D, AVRON A, TAMIR M, METZGER M, COHEN IR: Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, Phase II trial. Lancet (2001) 358:1749-1753. Report of a successful Phase II randomised controlled trial with an HSP peptide in diabetes.
111. KAPPOS L, COMI G, PANITCH H et al.: Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized Phase II trial. Nat. Med. (2000) 6:1176-1182. First randomised controlled trial of antigen-specific immunotherapy in an autoimmune disease. Halted due to hypersensitivity reactions; secondary analysis, however, did show clinical benefit and Th2 immune deviation in the patients treated with the APL.
112. BIELEKOVA B, GOODWIN B, RICHERT N et al.: Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a Phase II clinical trial with an altered peptide ligand. Nat. Med. (2000) 6:1167-1175.
113. PRAKKEN BJ, SAMODAL R, LE TD et al: Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA (2004) 101:4228-4233. Report of a Phase I trial in rheumatoid arthritis with an HSP peptide that successfully induced antigen-specific immune deviation.
114. VANDERLUGT C, MILLER SD: Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. Immunol. (2002) 2:85-95.